Multicenter observational study on adherence and acceptance of lapatinib treatment in patients with HER2+ metastatic breast cancer.
Raffaele Addeo(George Moore Community Clinic), S. Del Prete, Ferdinando Riccardi(Ospedale Antonio Cardarelli), L. Maiorino, Roberto Mabilia(Ospedale Sant'Anna), Pasquale Incoronato, M. Bianco, Antonio Febbraro(Fatebenefratelli Hospital), Bruno Vincenzi(Campus Bio Medico University Hospital), Agata Pisano(University of Campania "Luigi Vanvitelli"), E. Russo
Cited by 2
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
|Cancer Discovery|2020|183
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180